- Home
- QNCX vs IAE Comparison
QNCX vs IAE Comparison
Compare QNCX & IAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- IAE
- Stock Information
- Founded
- QNCX 2012
- IAE 2007
- Country
- QNCX United States
- IAE United States
- Employees
- QNCX N/A
- IAE N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- IAE Trusts Except Educational Religious and Charitable
- Sector
- QNCX Health Care
- IAE Finance
- Exchange
- QNCX Nasdaq
- IAE Nasdaq
- Market Cap
- QNCX 85.9M
- IAE 79.9M
- IPO Year
- QNCX 2019
- IAE N/A
- Fundamental
- Price
- QNCX $1.65
- IAE $7.55
- Analyst Decision
- QNCX Strong Buy
- IAE
- Analyst Count
- QNCX 6
- IAE 0
- Target Price
- QNCX $8.00
- IAE N/A
- AVG Volume (30 Days)
- QNCX 263.4K
- IAE 46.3K
- Earning Date
- QNCX 11-12-2025
- IAE 01-01-0001
- Dividend Yield
- QNCX N/A
- IAE 10.21%
- EPS Growth
- QNCX N/A
- IAE N/A
- EPS
- QNCX N/A
- IAE N/A
- Revenue
- QNCX N/A
- IAE N/A
- Revenue This Year
- QNCX N/A
- IAE N/A
- Revenue Next Year
- QNCX N/A
- IAE N/A
- P/E Ratio
- QNCX N/A
- IAE N/A
- Revenue Growth
- QNCX N/A
- IAE N/A
- 52 Week Low
- QNCX $0.69
- IAE $5.31
- 52 Week High
- QNCX $2.45
- IAE $6.45
- Technical
- Relative Strength Index (RSI)
- QNCX 56.09
- IAE 68.04
- Support Level
- QNCX $1.59
- IAE $7.40
- Resistance Level
- QNCX $1.68
- IAE $7.60
- Average True Range (ATR)
- QNCX 0.06
- IAE 0.09
- MACD
- QNCX 0.01
- IAE 0.00
- Stochastic Oscillator
- QNCX 69.57
- IAE 83.91
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.